Adverse events in trials of licensed drugs for irritable bowel syndrome with constipation or diarrhea: Systematic review and meta‐analysis

Nocebo effects occurring in patients receiving placebo frequently impact on adverse events reported in randomized controlled trials (RCTs) in irritable bowel syndrome (IBS). Therefore, we conducted a systematic review and meta‐analysis to assess the proportion of patients randomized to placebo or active drug experiencing any adverse event in trials of licensed drugs for IBS with constipation (IBS‐C) or diarrhea (IBS‐D), and to estimate the risk of developing adverse events among patients randomized to placebo.

[1]  Lin Chang,et al.  Efficacy of Linaclotide in Reducing Abdominal Symptoms of Bloating, Discomfort, and Pain: A Phase 3B Trial Using a Novel Abdominal Scoring System , 2021, The American journal of gastroenterology.

[2]  Shantanu H. Joshi,et al.  Effect of Exclusion Diets on Symptom Severity and the Gut Microbiota in Patients With Irritable Bowel Syndrome , 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[3]  A. Ford,et al.  British Society of Gastroenterology guidelines on the management of irritable bowel syndrome , 2021, Gut.

[4]  W. Chey,et al.  Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 26-Week, Placebo-Controlled Phase 3 Trial (T3MPO-2) , 2020, The American journal of gastroenterology.

[5]  W. Chey,et al.  Randomized Trial of 2 Delayed-Release Formulations of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation , 2020, The American journal of gastroenterology.

[6]  E. Savarino,et al.  Symptom Stability in Rome IV vs Rome III Irritable Bowel Syndrome. , 2020, The American journal of gastroenterology.

[7]  E. Savarino,et al.  Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. , 2020, The lancet. Gastroenterology & hepatology.

[8]  A. Ford,et al.  Relative Efficacy of Tegaserod in a Systematic Review and Network Meta-analysis of Licensed Therapies for Irritable Bowel Syndrome with Constipation. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[9]  W. Chey,et al.  Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1) , 2020, The American journal of gastroenterology.

[10]  P. Moayyedi,et al.  Efficacy of soluble fibre, antispasmodic drugs, and gut-brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis. , 2019, The lancet. Gastroenterology & hepatology.

[11]  J. Higgins,et al.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, International Coaching Psychology Review.

[12]  P. Moayyedi,et al.  Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis , 2019, Gut.

[13]  P. Moayyedi,et al.  Efficacy of Secretagogues in Patients With Irritable Bowel Syndrome With Constipation: Systematic Review and Network Meta-analysis. , 2018, Gastroenterology.

[14]  A. Drewes,et al.  Repeatability and effect of blinding of fructose breath tests in patients with functional gastrointestinal disorders , 2018, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[15]  D. Brenner,et al.  Efficacy and Safety of Eluxadoline in IBS-D Patients Who Report Inadequate Symptom Control With Prior Loperamide Use: A Phase 4, Multicenter, Multinational, Randomized, Placebo-controlled, Double-blinded Study (RELIEF): Presidential Poster Award , 2018, American Journal of Gastroenterology.

[16]  R. Collins,et al.  Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase , 2018, Yearbook of Paediatric Endocrinology.

[17]  F. Benedetti,et al.  Nocebo effects: more investigation is needed , 2018, Expert opinion on drug safety.

[18]  M. Currie,et al.  Linaclotide in irritable bowel syndrome with constipation: A Phase 3 randomized trial in China and other regions , 2018, Journal of gastroenterology and hepatology.

[19]  R. Fogel,et al.  Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials , 2018, The American Journal of Gastroenterology.

[20]  R. Collins,et al.  Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase , 2017, The Lancet.

[21]  M. Hongo,et al.  Optimal dose of ramosetron in female patients with irritable bowel syndrome with diarrhea: A randomized, placebo‐controlled phase II study , 2017, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[22]  A. Carroccio,et al.  Suspected Nonceliac Gluten Sensitivity Confirmed in Few Patients After Gluten Challenge in Double‐Blind, Placebo‐Controlled Trials , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[23]  W. Chey,et al.  Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial , 2017, The American Journal of Gastroenterology.

[24]  T. Okumura,et al.  Ramosetron Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women. , 2016, Gastroenterology.

[25]  L. Turner,et al.  Eluxadoline for Irritable Bowel Syndrome with Diarrhea. , 2016, The New England journal of medicine.

[26]  U. Bingel.  Avoiding nocebo effects to optimize treatment outcome. , 2014, JAMA.

[27]  S. Fukudo,et al.  Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[28]  J. Almenoff,et al.  Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study. , 2013, Gastroenterology.

[29]  L. Böhn,et al.  Self-Reported Food-Related Gastrointestinal Symptoms in IBS Are Common and Associated With More Severe Symptoms and Reduced Quality of Life , 2013, The American Journal of Gastroenterology.

[30]  W. Chey,et al.  Linaclotide for Irritable Bowel Syndrome With Constipation: A 26-Week, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Efficacy and Safety , 2012, The American Journal of Gastroenterology.

[31]  M. Currie,et al.  A 12-Week, Randomized, Controlled Trial With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Linaclotide in Irritable Bowel Syndrome With Constipation , 2012, The American Journal of Gastroenterology.

[32]  J. Ioannidis,et al.  Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials , 2011, BMJ : British Medical Journal.

[33]  W. Chey,et al.  Rifaximin therapy for patients with irritable bowel syndrome without constipation. , 2011, The New England journal of medicine.

[34]  M. Currie,et al.  Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. , 2010, Gastroenterology.

[35]  Michele Tarsilla.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, Journal of MultiDisciplinary Evaluation.

[36]  D. Drossman,et al.  Not all side effects associated with tricyclic antidepressant therapy are true side effects. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[37]  W. Chey,et al.  Clinical trial: lubiprostone in patients with constipation‐associated irritable bowel syndrome – results of two randomized, placebo‐controlled studies , 2009, Alimentary pharmacology & therapeutics.

[38]  K. Matsueda,et al.  A Phase II Trial of the Novel Serotonin Type 3 Receptor Antagonist Ramosetron in Japanese Male and Female Patients with Diarrhea-Predominant Irritable Bowel Syndrome , 2008, Digestion.

[39]  D. Drossman,et al.  Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation , 2008, Alimentary pharmacology & therapeutics.

[40]  M. Hongo,et al.  A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome , 2008, Scandinavian journal of gastroenterology.

[41]  S. Gordon,et al.  A Randomized, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of 0.5 mg and 1 mg Alosetron in Women With Severe Diarrhea-predominant IBS , 2007, The American Journal of Gastroenterology.

[42]  Sunil Kumar,et al.  Effect of tegaserod on colonic transit time in male patients with constipation‐predominant irritable bowel syndrome , 2007, Journal of gastroenterology and hepatology.

[43]  D. Drossman,et al.  What Patients Know About Irritable Bowel Syndrome (IBS) and What They Would Like to Know. National Survey on Patient Educational Needs in IBS and Development and Validation of the Patient Educational Needs Questionnaire (PEQ) , 2007, The American Journal of Gastroenterology.

[44]  J. Avorn,et al.  Medication-attributed adverse effects in placebo groups: implications for assessment of adverse effects. , 2006, Archives of internal medicine.

[45]  L. Chang,et al.  A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation , 2005, Gut.

[46]  E. Mayer,et al.  A Dose-Ranging, Phase II Study of the Efficacy and Safety of Alosetron in Men with Diarrhea-Predominant IBS , 2005, The American Journal of Gastroenterology.

[47]  I. Holme,et al.  A double‐blind, placebo‐controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome , 2004, Scandinavian journal of gastroenterology.

[48]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[49]  H. Yuen,et al.  An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome , 2003, Gut.

[50]  M. Lefkowitz,et al.  A randomized, double‐blind, placebo‐controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation , 2002, Alimentary pharmacology & therapeutics.

[51]  F. Pace,et al.  Tegaserod, a 5‐HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation , 2001, Alimentary pharmacology & therapeutics.

[52]  P. Jhingran,et al.  Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome , 2001, American Journal of Gastroenterology.

[53]  M. Camilleri,et al.  A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. , 2001, Archives of internal medicine.

[54]  Ulf Bengtsson,et al.  Food-Related Gastrointestinal Symptoms in the Irritable Bowel Syndrome , 2001, Digestion.

[55]  M. Camilleri,et al.  Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial , 2000, The Lancet.

[56]  D. Drossman,et al.  Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5‐HT3 receptor antagonist , 1999, Alimentary pharmacology & therapeutics.

[57]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[58]  N. Talley,et al.  The Irritable Bowel Syndrome: Long-Term Prognosis and the Physician-Patient Interaction , 1995, Annals of Internal Medicine.

[59]  G. Sturniolo,et al.  [Irritable bowel syndrome]. , 1988, Giornale di clinica medica.

[60]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[61]  U. Bingel,et al.  Nocebo Effects: Neurobiological Mechanisms and Strategies for Prevention and Optimizing Treatment. , 2018, International review of neurobiology.

[62]  L. Vase,et al.  Can knowledge of Placebo and Nocebo Mechanisms Help Improve Randomized Clinical Trials? , 2018, International review of neurobiology.